Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Arcus Biosciences, Inc. (NYSE:RCUS) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $30.00.

Several brokerages recently commented on RCUS. Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, January 18th. The Goldman Sachs Group upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $16.00 to $28.00 in a research report on Monday, January 12th. UBS Group reiterated a “buy” rating on shares of Arcus Biosciences in a report on Monday, December 15th. Wedbush set a $35.00 price target on Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Finally, Bank of America upped their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th.

Insider Activity

In other Arcus Biosciences news, President Juan C. Jaen sold 31,823 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $21.41, for a total value of $681,330.43. Following the completion of the sale, the president directly owned 922,240 shares of the company’s stock, valued at $19,745,158.40. The trade was a 3.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Carolyn C. Tang sold 6,810 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total transaction of $150,909.60. Following the completion of the transaction, the general counsel owned 124,734 shares in the company, valued at $2,764,105.44. This represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 315,887 shares of company stock valued at $7,087,692. Insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RCUS. GAMMA Investing LLC raised its holdings in shares of Arcus Biosciences by 17.5% in the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after purchasing an additional 482 shares in the last quarter. Amalgamated Bank increased its holdings in Arcus Biosciences by 3.9% during the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $266,000 after buying an additional 736 shares during the period. Creative Planning raised its stake in Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after buying an additional 771 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in Arcus Biosciences by 1.1% during the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock worth $2,203,000 after buying an additional 1,000 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Arcus Biosciences by 8.0% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock worth $142,000 after buying an additional 1,294 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Stock Up 2.7%

Shares of RCUS opened at $21.60 on Tuesday. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The business has a fifty day moving average of $23.21 and a 200 day moving average of $17.15. The company has a market cap of $2.33 billion, a PE ratio of -6.28 and a beta of 0.84. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $26.40.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.01. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. Arcus Biosciences’s revenue for the quarter was down 45.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.00) EPS. On average, sell-side analysts expect that Arcus Biosciences will post -3.15 EPS for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.